{"disease":{"id":"non-myeloid-malignancy","name":"non myeloid malignancy"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04466137","title":"Phase 3 Study to Evaluate the Safety and Efficacy of YPEG-rhG-CSF in Malignancies Receiving Chemotherapy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":398,"lead_sponsor_name":"Xiamen Amoytop Biotech Co., Ltd.","has_results":false},{"nct_id":"NCT04662892","title":"An Analysis to Estimate Febrile Neutropenia (FN) in Patients Receiving Udenyca","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Coherus Oncology, Inc.","has_results":false},{"nct_id":"NCT03878524","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}